# Masuo Kondoh

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 103 papers | 2,611 citations | 186209 28 h-index | 233338 45 g-index |
| 111 all docs | 111 docs citations | 111 times ranked | 2226 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Silica nanoparticles as hepatotoxicants. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 496-501. | 2.0 | 209 |
| 2 | A Novel Strategy for the Enhancement of Drug Absorption Using a Claudin Modulator. Molecular Pharmacology, 2005, 67, 749-756. | 1.0 | 134 |
| 3 | Histological analysis of 70-nm silica particles-induced chronic toxicity in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 626-629. | 2.0 | 80 |
| 4 | A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide. Biochemical Pharmacology, 2010, 79, 1437-1444. | 2.0 | 77 |
| 5 | Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4. Journal of Controlled Release, 2005, 108, 56-62. | 4.8 | 73 |
| 6 | Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of Clostridium perfringens enterotoxin, by site-directed mutagenesis. Biochemical Pharmacology, 2008, 75, 1639-1648. | 2.0 | 73 |
| 7 | A Novel Tumor-Targeted Therapy Using a Claudin-4-Targeting Molecule. Molecular Pharmacology, 2009, 76, 918-926. | 1.0 | 71 |
| 8 | Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection. Biochemical and Biophysical Research Communications, 2011, 416, 119-124. | 1.0 | 63 |
| 9 | Preparation of a Claudin-Targeting Molecule Using a C-Terminal Fragment of Clostridium perfringens Enterotoxin. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 255-260. | 1.3 | 60 |
| 10 | A Novel Strategy for a Drug Delivery System Using a Claudin Modulator. Biological and Pharmaceutical Bulletin, 2006, 29, 1783-1789. | 0.6 | 59 |
| 11 | Acute and chronic nephrotoxicity of platinum nanoparticles in mice. Nanoscale Research Letters, 2013, 8, 395. | 3.1 | 59 |
| 12 | Angubindin-1 opens the bloodâ€"brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. Journal of Controlled Release, 2018, 283, 126-134. | 4.8 | 51 |
| 13 | Monoclonal Antibodies against Extracellular Domains of Claudin-1 Block Hepatitis C Virus Infection in a Mouse Model. Journal of Virology, 2015, 89, 4866-4879. | 1.5 | 48 |
| 14 | Angubindin-1, a novel paracellular absorption enhancer acting at the tricellular tight junction. Journal of Controlled Release, 2017, 260, 1-11. | 4.8 | 48 |
| 15 | C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine. PLoS ONE, 2015, 10, e0126352. | 1.1 | 47 |
| 16 | Role of tyrosine residues in modulation of claudin-4 by the C-terminal fragment of Clostridium perfringens enterotoxin. Biochemical Pharmacology, 2007, 73, 206-214. | 2.0 | 45 |
| 17 | Creation and biochemical analysis of a broad-specific claudin binder. Biomaterials, 2012, 33, 3464-3474. | 5.7 | 45 |
| 18 | Claudin-5-Binders Enhance Permeation of Solutes across the Blood-Brain Barrier in a Mammalian Model. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 275-283. | 1.3 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Targeting tight junction proteins-significance for drug development. Drug Discovery Today, 2008, 13, 180-186. | 3.2 | 43 |
| 20 | Mucosal vaccination using claudin-4-targeting. Biomaterials, 2010, 31, 5463-5471. | 5.7 | 41 |
| 21 | Brain endothelial tricellular junctions as novel sites for T cell diapedesis across the bloodâ€“brain barrier. Journal of Cell Science, 2021, 134, . | 1.2 | 37 |
| 22 | Development of an Antiâ€“Claudin-3 and -4 Bispecific Monoclonal Antibody for Cancer Diagnosis and Therapy. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 206-213. | 1.3 | 34 |
| 23 | Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer. Cancer Letters, 2015, 369, 212-221. | 3.2 | 34 |
| 24 | Role of Tyr306 in the C-terminal fragment of Clostridium perfringens enterotoxin for modulation of tight junction. Biochemical Pharmacology, 2007, 73, 824-830. | 2.0 | 33 |
| 25 | Anti-claudin-4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancer. Oncotarget, 2018, 9, 37367-37378. | 0.8 | 32 |
| 26 | Spiral progression in the development of absorption enhancers based on the biology of tight junctions. Advanced Drug Delivery Reviews, 2012, 64, 515-522. | 6.6 | 31 |
| 27 | Hepatitis C Virus Entry Is Impaired by Claudin-1 Downregulation in Diacylglycerol Acyltransferase-1-Deficient Cells. Journal of Virology, 2014, 88, 9233-9244. | 1.5 | 30 |
| 28 | Anti-HCV effect of Lentinula edodes mycelia solid culture extracts andÂlow-molecular-weight lignin. Biochemical and Biophysical Research Communications, 2015, 462, 52-57. | 1.0 | 28 |
| 29 | Engineered membrane protein antigens successfully induce antibodies against extracellular regions of claudin-5. Scientific Reports, 2018, 8, 8383. | 1.6 | 28 |
| 30 | Potential for Tight Junction Proteinâ€“Directed Drug Development Using Claudin Binders and Angubindin-1. International Journal of Molecular Sciences, 2019, 20, 4016. | 1.8 | 28 |
| 31 | Role of N-Terminal Amino Acids in the Absorption-Enhancing Effects of the C-Terminal Fragment ofClostridium perfringensEnterotoxin. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 789-795. | 1.3 | 27 |
| 32 | Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model. Journal of Virology, 2018, 92, . | 1.5 | 27 |
| 33 | Targeting claudinâ€4 enhances chemosensitivity in breast cancer. Cancer Science, 2020, 111, 1840-1850. | 1.7 | 27 |
| 34 | A Claudin-Targeting Molecule as an Inhibitor of Tumor Metastasis. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 576-582. | 1.3 | 26 |
| 35 | Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte Model. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 440-447. | 1.3 | 26 |
| 36 | Progress in absorption enhancers based on tight junction. Expert Opinion on Drug Delivery, 2007, 4, 275-286. | 2.4 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Homoharringtonine increases intestinal epithelial permeability by modulating specific claudin isoforms in Caco-2 cell monolayers. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 232-238. | 2.0 | 24 |
| 38 | Efficacy and safety evaluation of claudinâ€4â€targeted antitumor therapy using a human and mouse crossâ€reactive monoclonal antibody. Pharmacology Research and Perspectives, 2016, 4, e00266. | 1.1 | 24 |
| 39 | Tight junction modulator and drug delivery. Expert Opinion on Drug Delivery, 2009, 6, 509-515. | 2.4 | 22 |
| 40 | Occludin-Knockout Human Hepatic Huh7.5.1-8-Derived Cells Are Completely Resistant to Hepatitis C Virus Infection. Biological and Pharmaceutical Bulletin, 2016, 39, 839-848. | 0.6 | 22 |
| 41 | Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers. Pflugers Archiv European Journal of Physiology, 2017, 469, 45-53. | 1.3 | 22 |
| 42 | Clostridium perfringens enterotoxin induces claudin-4 to activate YAP in oral squamous cell carcinomas. Oncotarget, 2020, 11, 309-321. | 0.8 | 22 |
| 43 | Mutated C-terminal fragments of Clostridium perfringens enterotoxin have increased affinity to claudin-4 and reversibly modulate tight junctions in vitro. Biochemical and Biophysical Research Communications, 2011, 410, 466-470. | 1.0 | 21 |
| 44 | Discovery of Antiâ€"Claudin-1 Antibodies as Candidate Therapeutics against Hepatitis C Virus. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 112-118. | 1.3 | 21 |
| 45 | Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell line. Histochemistry and Cell Biology, 2020, 153, 5-16. | 0.8 | 21 |
| 46 | Claudin-4-targeting of diphtheria toxin fragment A using a C-terminal fragment of Clostridium perfringens enterotoxin. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 213-217. | 2.0 | 20 |
| 47 | Claudin-binder C-CPE mutants enhance permeability of insulin across human nasal epithelial cells. Drug Delivery, 2016, 23, 2703-2710. | 2.5 | 20 |
| 48 | Development of a Quenchbody for the Detection and Imaging of the Cancer-Related Tight-Junction-Associated Membrane Protein Claudin. Analytical Chemistry, 2017, 89, 10783-10789. | 3.2 | 20 |
| 49 | Claudin-5: A Pharmacological Target to Modify the Permeability of the Bloodâ€"Brain Barrier. Biological and Pharmaceutical Bulletin, 2021, 44, 1380-1390. | 0.6 | 20 |
| 50 | Cellular internalization, transcellular transport, and cellular effects of silver nanoparticles in polarized Caco-2 cells following apical or basolateral exposure. Biochemical and Biophysical Research Communications, 2017, 484, 543-549. | 1.0 | 19 |
| 51 | Claudinâ€targeted drug development using antiâ€claudin monoclonal antibodies to treat hepatitis and cancer. Annals of the New York Academy of Sciences, 2017, 1397, 5-16. | 1.8 | 18 |
| 52 | Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay. Scientific Reports, 2017, 7, 14514. | 1.6 | 18 |
| 53 | Comparison of mucosal absorption-enhancing activity between a claudin-3/-4 binder and a broadly specific claudin binder. Biochemical and Biophysical Research Communications, 2012, 423, 229-233. | 1.0 | 17 |
| 54 | Proof of concept for claudinâ€targeted drug development. Annals of the New York Academy of Sciences, 2012, 1258, 65-70. | 1.8 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Endothelial Cellâ€“Specific Expression of Roundabout 4 Is Regulated by Differential DNA Methylation of the Proximal Promoter. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1531-1538. | 1.1 | 16 |
| 56 | Epithelial barrier dysfunction and cell migration induction via JNK/cofilin/actin by angubindin-1. Tissue Barriers, 2020, 8, 1695475. | 1.6 | 16 |
| 57 | Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase bloodâ€“brain barrier permeability for drug delivery to the brain in a non-human primate. Journal of Controlled Release, 2021, 336, 105-111. | 4.8 | 16 |
| 58 | Creation of a Claudin-2 Binder and Its Tight Junctionâ€“Modulating Activity in a Human Intestinal Model. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 444-451. | 1.3 | 15 |
| 59 | Tissue distribution and safety evaluation of a claudin-targeting molecule, the C-terminal fragment of Clostridium perfringens enterotoxin. European Journal of Pharmaceutical Sciences, 2014, 52, 132-137. | 1.9 | 14 |
| 60 | Checkpoint Kinase 1 Activation Enhances Intestinal Epithelial Barrier Function via Regulation of Claudin-5 Expression. PLoS ONE, 2016, 11, e0145631. | 1.1 | 14 |
| 61 | Development of Adjuvant-Free Bivalent Food Poisoning Vaccine by Augmenting the Antigenicity of Clostridium perfringens Enterotoxin. Frontiers in Immunology, 2018, 9, 2320. | 2.2 | 14 |
| 62 | Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer. Journal of Nuclear Medicine, 2020, 61, 1756-1763. | 2.8 | 13 |
| 63 | A Novel Screening System for Claudin Binder Using Baculoviral Display. PLoS ONE, 2011, 6, e16611. | 1.1 | 13 |
| 64 | Epinephrine is an enhancer of rat intestinal absorption. Journal of Controlled Release, 2005, 102, 563-568. | 4.8 | 12 |
| 65 | Peptides as Tight Junction Modulators. Current Pharmaceutical Design, 2011, 17, 2699-2703. | 0.9 | 12 |
| 66 | Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2. European Journal of Pharmaceutical Sciences, 2018, 117, 161-167. | 1.9 | 12 |
| 67 | The Clinical Innovation Network: a policy for promoting development of drugs and medical devices in Japan. Drug Discovery Today, 2019, 24, 4-8. | 3.2 | 12 |
| 68 | Tight Junction Modulating Bioprobes for Drug Delivery System to the Brain: A Review. Pharmaceutics, 2020, 12, 1236. | 2.0 | 12 |
| 69 | Tight junction modulators for drug delivery to the central nervous system. Drug Discovery Today, 2020, 25, 1477-1486. | 3.2 | 12 |
| 70 | A simple reporter assay for screening claudin-4 modulators. Biochemical and Biophysical Research Communications, 2012, 426, 454-460. | 1.0 | 11 |
| 71 | The application of an alanine-substituted mutant of the C-terminal fragment of Clostridium perfringens enterotoxin as a mucosal vaccine in mice. Biomaterials, 2012, 33, 317-324. | 5.7 | 11 |
| 72 | Generation and characterization of a humanâ€“mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model. Biochemical and Biophysical Research Communications, 2016, 477, 91-95. | 1.0 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Current progress in a second-generation claudin binder, anti-claudin antibody, for clinical applications. Drug Discovery Today, 2016, 21, 1711-1718. | 3.2 | 11 |
| 74 | Impaired airway mucociliary function reduces antigen-specific IgA immune response to immunization with a claudin-4-targeting nasal vaccine in mice. Scientific Reports, 2018, 8, 2904. | 1.6 | 11 |
| 75 | Anti-Claudin Antibodies as a Concept for Development of Claudin-Directed Drugs. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 179-186. | 1.3 | 11 |
| 76 | Lignosulfonic acid attenuates NF-ÎºB activation and intestinal epithelial barrier dysfunction induced by TNF-Î±/IFN-Î³ in Caco-2 cells. Journal of Natural Medicines, 2018, 72, 448-455. | 1.1 | 10 |
| 77 | Anti-tumor effect of a recombinant Bifidobacterium strain secreting a claudin-targeting molecule in a mouse breast cancer model. European Journal of Pharmacology, 2020, 887, 173596. | 1.7 | 10 |
| 78 | Recent Advances in Claudin-Targeting Technology. Biological and Pharmaceutical Bulletin, 2013, 36, 708-714. | 0.6 | 9 |
| 79 | Claudinâ€4 binder Câ€CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a <scp>MAPK</scp> pathway. Pharmacology Research and Perspectives, 2015, 3, e00196. | 1.1 | 9 |
| 80 | Pathological changes in tight junctions and potential applications into therapies. Drug Discovery Today, 2012, 17, 727-732. | 3.2 | 7 |
| 81 | The Roadmap to Approval under Japanâ€™s Two-Track Regulatory System: Comparing Six Regenerative Medical Products. Cell Stem Cell, 2020, 27, 515-518. | 5.2 | 6 |
| 82 | Modifying the bloodâ€“brain barrier by targeting claudinâ€5: Safety and risks. Annals of the New York Academy of Sciences, 2022, 1514, 62-69. | 1.8 | 6 |
| 83 | Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection. Biochemical and Biophysical Research Communications, 2019, 514, 785-790. | 1.0 | 5 |
| 84 | Characterization of monoclonal antibodies recognizing each extracellular loop domain of occludin. Journal of Biochemistry, 2019, 166, 297-308. | 0.9 | 5 |
| 85 | A Concept for a Japanese Regulatory Framework for Emerging Medical Devices with Frequently Modified Behavior. Clinical and Translational Science, 2020, 13, 877-879. | 1.5 | 5 |
| 86 | Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval. Clinical and Translational Science, 2021, 14, 806-811. | 1.5 | 5 |
| 87 | Effects of HMGB1 on Tricellular Tight Junctions via TGF-Î² Signaling in Human Nasal Epithelial Cells. International Journal of Molecular Sciences, 2021, 22, 8390. | 1.8 | 5 |
| 88 | Adenovirus vector-mediated assay system for hepatitis C virus replication. Nucleic Acids Research, 2011, 39, e64-e64. | 6.5 | 4 |
| 89 | Use of cell-based screening to identify small-molecule compounds that modulate claudin-4 expression. Biotechnology Letters, 2015, 37, 1177-1185. | 1.1 | 4 |
| 90 | A Method to Prepare Claudin-Modulating Recombinant Proteins. Methods in Molecular Biology, 2019, 2109, 251-260. | 0.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A Review of the Regulatory Framework for Initiation and Acceleration of Patient Access to Innovative Medical Products in Japan. Clinical Pharmacology and Therapeutics, 2019, 106, 508-511. | 2.3 | 4 |
| 92 | New Japanese Regulatory Frameworks for Post-Marketing Management of Pharmaceutical Products. Pharmaceutical Research, 2020, 37, 122. | 1.7 | 4 |
| 93 | A Method to Prepare a Bioprobe for Regulatory Science of the Drug Delivery System to the Brain: An Angulin Binder to Modulate Tricellular Tight Junction-Seal. Methods in Molecular Biology, 2020, 2367, 291-304. | 0.4 | 2 |
| 94 | Occludinâ€binding singleâ€chain variable fragment and antigenâ€binding fragment antibodies prevent hepatitis C virus infection. FEBS Letters, 2021, 595, 220-229. | 1.3 | 2 |
| 95 | Translocation of LSR from tricellular corners causes macropinocytosis at cellâ€“cell interface as a trigger for breaking out of contact inhibition. FASEB Journal, 2021, 35, e21742. | 0.2 | 2 |
| 96 | Silica nanoparticle-induced toxicity in mouse lung and liver imaged by electron microscopy. Fundamental Toxicological Sciences, 2015, 2, 19-23. | 0.2 | 1 |
| 97 | Legislation on the Roles of the Pharmacist and Pharmacy in the Revision of the Pharmaceutical and Medical Device Act and the Pharmacists Act in Japan. Therapeutic Innovation and Regulatory Science, 2021, 55, 304-308. | 0.8 | 1 |
| 98 | A novel screening system for claudin binder using baculoviral display. FASEB Journal, 2010, 24, 773.3. | 0.2 | 0 |
| 99 | Development of drug delivery system based on biology of epithelial barrier : 19<sup>th</sup> Nagai Award, Japan Society of DDS. Drug Delivery System, 2019, 34, 279-283. | 0.0 | 0 |
| 100 | Development of drug delivery system for treatment of central nervous system diseases targeting tight junctions. Drug Delivery System, 2019, 34, 374-384. | 0.0 | 0 |
| 101 | [FOREWORD]Interpenetration of innovation and regulation for drug development. Drug Delivery System, 2019, 34, 333-333. | 0.0 | 0 |
| 102 | Therapeutic innovation and regulatory sciences for paracellular absorption enhancers for biologics. Drug Delivery System, 2020, 35, 20-26. | 0.0 | 0 |
| 103 | Homoharringtonine is a transdermal granular permeation enhancer. Biochemical and Biophysical Research Communications, 2022, , . | 1.0 | 0 |